Screening for ADAMTS13 Gene Mutations in Thrombotic Thrombocytopenic Purpura Reveals a New Deletional Mutation.

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 2300-2300
Author(s):  
Teresa Fidalgo ◽  
Patricia Martinho ◽  
Ramon Salvado ◽  
Catarina Silva Pinto ◽  
Dalila Marques ◽  
...  

Abstract Thrombotic Thrombocytopenic Purpura (TTP) is a rare severe thrombotic microangiopathy due to the presence of ultra large von Willebrand factor (UL-vWF) multimers in circulation. The aetiology has been linked to a congenital deficiency or inhibition of the vWF-cleaving protease (ADAMTS-13) activity by autoantibodies, which neutralise the enzymatic activity or bind the protease, increasing the plasmatic clearance (non-neutralising). The presence of autoantibodies can be associated with mutations and polymorphisms (SNPs) in the ADAMTS-13 gene. The goal of this study was to characterize the ADAMTS-13 in 4 female patients with acute TTP episodes. The clinical picture was characterized by neurological symptoms and microangiopathic hemolytic anemia (Hb 6 – 9 g/dL), thrombocytopenia (platelets 4 – 47 x109/L), elevated LDH (1874 – 4922 IU/mL). In one patient TTP episodes occurred during 4 pregnancies resulting in fetal deaths; one patient has systemic lupus. No precipitant factors were identified in the other 2 women; 1 of them had 3 TTP episodes. Methodology: ADAMTS-13 antigen and IgG anti-ADAMTS-13 were studied by ELISA (American Diagnostica). The vWF multimeric pattern was analyzed by SDS electroforesis, Western Blot, imunofixation and densitometry. Mutations screening along the 29 exons and boundaries of the ADAMTS-13 gene was performed by direct sequencing. Results: All the patients presented UL-vWF and autoantibodies anti-ADAMTS-13 and decreased ADAMTS-13 antigen. ADAMTS-13 gene studies identified SNPs in the four patients and mutations 764_776 del12 and R1096H, in heterozygosity, in the two patients with TTP associated with pregnancy and lupus, respectively. ADAMTS13 ADAMTS13 gene Patients Age TTP UL vWF Ag (ng/ml) IgG (AU/ml) Mutation Modulators SNPs Reference range: Ag: 485–1242 ng/ul; IgG: cutoff >13.9 AU/ml; *3 episodes; **4 episodes I 73 idiopatic + <62.5 18 (pos) No mut R7W (Htz); Q488E (Hm); II 41 Idiopatic* + 127 20.3 (pos) No mut R7W (Hm); Q488E (Hm)
 P618A (Hm); A732V (Hm) III 32 lupus + 284 30 (pos) E25, R1096H (Htz) R7W (Htz); Q488E (Hm) IV 26 Pregnancy** + <62.5 22.6 (pos) E7, 764_776del12 (Htz) R625H (Hm) Discussion: PTT in these four patients was associated with antibodies anti-ADAMTS-13 and low levels of protein. Identification of the R7W and Q488E SNPs, described as positive modulators of protein secretion, on Patient I suggests the presence of the non-neutralising type of antibodies responsible for an increased plasmatic protein clearance. The positive modulation of the same SNPs on Patient II and III may be abolished by the presence of SNPs P618A and A732V (Camilleri et al; Pleimaueur et al) on Patient II and the mutation R1096H (Meyer et al) on Patient III. The not previously described mutation 764_776del12, identified on Patient IV, is likely to disturb the protein aminoacid composition, compromising the protease structure and function. This patient had a PTT episode in each of her four pregnancies.

Blood ◽  
2006 ◽  
Vol 108 (11) ◽  
pp. 3965-3965
Author(s):  
Nam Keun Kim ◽  
Moon Ju Jang ◽  
Sun Kim ◽  
Sun Ju Lee ◽  
Hye Won Park ◽  
...  

Abstract ADAMTS-13 is an enzyme which cleave von Willebrand factor (VWF) to prevent excessive platelet thrombus formation. Mutation of ADAMTS-13 is associated with congenital thrombotic thrombocytopenic purpura (TTP). In this study, we report three novel missense mutations of ADAMTS-13 gene in TTP families. Genetic analysis of ADAMTS-13 gene was performed in 6 TTP families. Three novel ADAMTS-13 gene mutations (2708C>T [S903L], 3650T>C [I1217T] and 3941C>T [S1314L]) detected in 3 families. They were all found with heterozygous genotype in exon 21, 26 and 28, respectively. The 3650T>C mutation was found at exon 26 in the patient and his mother. A heterozygous guanine to adenine substitution was found at 5′ splicing site of intron 3(IVS+ 1) in the patient, his brother and his father. The plasma ADAMTS-13 activities of the patient, father, mother, and brother were less than 3%, 56%, 55% and 62% respectively. ADAMTS-13 inhibitors were not detected in all family members. 3941C>T was found at exon 28 in the patient and her father. The plasma ADAMTS-13 activities of the patient, father, and mother were 96%, 83%, and 83% respectively.


Blood ◽  
2020 ◽  
Author(s):  
George Goshua ◽  
Pranay Sinha ◽  
Jeanne Elise Hendrickson ◽  
Christopher A Tormey ◽  
Pavan Bendapudi ◽  
...  

Acquired thrombotic thrombocytopenic purpura (TTP) is a life-threatening disease characterized by thrombotic microangiopathy leading to end-organ damage. The standard of care (SOC) treatment is therapeutic plasma exchange (TPE) alongside immunomodulation with steroids, with increasing use of rituximab +/- other immunomodulatory agents. The addition of caplacizumab, a nanobody targeting von Willebrand factor, was shown to accelerate platelet count recovery and reduce TPE treatments and hospital length of stay in TTP patients treated in the TITAN and HERCULES trials. The addition of caplacizumab to SOC also led to increased bleeding due to transient reductions in von Willebrand factor and increased relapse rates. Using data from TITAN and HERCULES on caplacizumab, we performed the first-ever cost effectiveness analysis in TTP. Over a 5-year period, the projected incremental cost effectiveness ratio (ICER) in our Markov model was $1,482,260, significantly above the accepted 2019 US willingness-to-pay of $195,300. One-way sensitivity analyses showed the utility of the well state and the cost of caplacizumab to have the largest effects on ICER, with a reduction in caplacizumab cost demonstrating the greatest impact on lowering the ICER. In a probabilistic sensitivity analysis, SOC was favored over caplacizumab in 100% of 10,000 iterations. Our data indicate that the addition of caplacizumab to SOC in treatment of acquired TTP is not cost effective due to the high cost of the medication and its failure to improve relapse rates. The potential impact of caplacizumab on health system cost using longer-term follow-up data merits further study.


Sign in / Sign up

Export Citation Format

Share Document